Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: A case report

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 7, 2008, Pages 591-593

  Wu, Ziqiang ^a,b   Sadda, Srinivas R ^a  

^a DOHENY EYE INSTITUTE   (United States)

^b Center for Advanced Eye Care   (United States)

Author keywords

Side effects; Uninjected eye

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE REPORT; CATARACT; CATARACT EXTRACTION; DRUG EFFECT; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LENS IMPLANT; MALE; OPTICAL COHERENCE TOMOGRAPHY; REPEATED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; TREATMENT OUTCOME; VITRECTOMY;

EID: 49449089535     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
2. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47.
3. Letter to Healthcare Provider: Available at: http://www.gene.com/gene/ products/information/pdf/healthcare-provider-letter.pdf. Accessed 27 September 2007.
4. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
5. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-6.
6. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
7. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141-9.
8. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309-15.
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
10. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-12.